Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 19/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12048710 | 0.98 | TLR7 (0.50) | TLR7MEN1MAPTKMT2ARXFP1 | |
| SCHEMBL2389379 | 0.95 | TLR7 (0.51) | TLR7MEN1MAPTKMT2ARXFP1 | |
| SCHEMBL4131635 | 0.88 | TLR7 (0.54) | TLR7 | |
| SCHEMBL14024986 | 0.86 | TLR7 (0.52) | TLR7 | |
| SCHEMBL2390264 | 0.86 | TLR7 (0.50) | TLR7 | |
| SCHEMBL20275365 | 0.85 | TLR7 (0.53) | TLR7 | |
| SCHEMBL12028529 | 0.83 | KMT2A (0.53) | MEN1MAPTKMT2ARXFP1 | |
| SCHEMBL566897 | 0.82 | TLR7 (0.53) | TLR7 | |
| SCHEMBL728835 | 0.82 | TLR7 (0.50) | TLR7 | |
| SCHEMBL12028553 | 0.81 | KMT2A (0.50) | MEN1MAPTKMT2ARXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1728793-B1 | 9-SUBSTITUTED 8-OXOADENINE COMPOUND | SUMITOMO DAINIPPON PHARMA CO LTD (JP) | 2016-02-03 | — | — | EP | disclosed |
| US-8969362-B2 | 9-substituted 8-oxoadenine compound | ASTRAZENECA AKTIEBOLAG (SE) | 2015-03-03 | — | — | US | disclosed |
| US-20140045837-A1 | 9-Substituted 8-Oxoadenine Compound | ASTRAZENECA AKTIEBOLAG (SE) | 2014-02-13 | — | — | US | disclosed |
| US-8575181-B2 | Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases | GLAXOSMITHKLINE LLC (US) | 2013-11-05 | — | — | US | disclosed |
| US-8575180-B2 | 9-substituted 8-oxoadenine compound | ASTRAZENECA AKTIEBOLAG (SE) | 2013-11-05 | — | — | US | disclosed |
| US-8575181-B2 | Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases | GLAXOSMITHKLINE LLC (US) | 2013-11-05 | — | — | US | disclosed |
| US-8575181-B2 | Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases | GLAXOSMITHKLINE LLC (US) | 2013-11-05 | — | — | US | disclosed |
| EP-2326646-B1 | PURINE DERIVATIVES FOR USE IN THE TREATMENT OF ALLERGIC, INFLAMMATORY AND INFECTIOUS DISEASES | GLAXOSMITHKLINE LLC (US) | 2013-07-31 | — | — | EP | disclosed |
| EP-2326646-B1 | PURINE DERIVATIVES FOR USE IN THE TREATMENT OF ALLERGIC, INFLAMMATORY AND INFECTIOUS DISEASES | GLAXOSMITHKLINE LLC (US) | 2013-07-31 | — | — | EP | disclosed |
| US-8138172-B2 | 8-oxoadenine derivatives acting as modulators of TLR7 | ASTRAZENECA AB (SE) | 2012-03-20 | — | — | US | disclosed |
| US-20110135670-A1 | PURINE DERIVATIVES FOR USE IN THE TREATMENT OF ALLERGIC, INFLAMMATORY AND INFECTIOUS DISEASES | GLAXOSMITHKLINE LLC (US) | 2011-06-09 | — | — | US | disclosed |
| US-20110135670-A1 | PURINE DERIVATIVES FOR USE IN THE TREATMENT OF ALLERGIC, INFLAMMATORY AND INFECTIOUS DISEASES | GLAXOSMITHKLINE LLC (US) | 2011-06-09 | — | — | US | disclosed |
| US-20110135670-A1 | PURINE DERIVATIVES FOR USE IN THE TREATMENT OF ALLERGIC, INFLAMMATORY AND INFECTIOUS DISEASES | GLAXOSMITHKLINE LLC (US) | 2011-06-09 | — | — | US | disclosed |
| US-20100240623-A1 | 8-OXOADENINE DERIVATIVES ACTING AS MODULATORS OF TLR7 | ASTRAZENECA AB (SE) | 2010-09-23 | — | — | US | disclosed |
| US-20100087443-A1 | 9-SUBSTITUTED-8-OXO-ADENINE COMPOUNDS AS TOLL-LIKE RECEPTOR (TLR7) MODULATORS | ASTRAZENECA AB (SE) | 2010-04-08 | — | — | US | disclosed |
| WO-2010018130-A1 | PURINE DERIVATIVES FOR USE IN THE TREATMENT OF ALLERGIC, INFLAMMATORY AND INFECTIOUS DISEASES | SMITHKLINE BEECHAM CORPORATION (US) | 2010-02-18 | — | — | WO | disclosed |
| EP-2041135-A1 | 8-OXOADENINE DERIVATIVES ACTING AS MODULATORS OF TLR7 | Astra Zeneca AB (SE) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008004948-A1 | 8-OXOADENINE DERIVATIVES ACTING AS MODULATORS OF TLR7 | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | WO | disclosed |
| US-20070190071-A1 | 9-Substituted 8-oxoadenine compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-08-16 | — | — | US | disclosed |
| US-20070190071-A1 | 9-Substituted 8-oxoadenine compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110135670-A1 | PURINE DERIVATIVES FOR USE IN THE TREATMENT OF ALLERGIC, INFLAMMATORY AND INFECTIOUS DISEASES | IFNAR1, IFNG, STING1 | TLR7 19/4885MEN1 812/4885MAPT 4629/4885 |
| US-20070190071-A1 | 9-Substituted 8-oxoadenine compound | IFNAR1, IL5, IFNG | TLR7 8/4885MEN1 4817/4885MAPT 4844/4885 |
| US-20100240623-A1 | 8-OXOADENINE DERIVATIVES ACTING AS MODULATORS OF TLR7 | TLR7, TLR8, TLR9 | TLR7 1/4885MEN1 4372/4885MAPT 3715/4885 |
| US-20100087443-A1 | 9-SUBSTITUTED-8-OXO-ADENINE COMPOUNDS AS TOLL-LIKE RECEPTOR (TLR7) MODULATORS | TLR9, TLR7, TLR1 | TLR7 2/4885MEN1 4389/4885MAPT 4259/4885 |
| US-20140045837-A1 | 9-Substituted 8-Oxoadenine Compound | IFNAR1, IL5, IFNG | TLR7 13/4885MEN1 4802/4885MAPT 4853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.